CERE stock icon

Cerevel Therapeutics
CERE

$41.68
0.41%
 

About: Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Employees: 355

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 46 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

59% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 49

21% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 34

4% more funds holding

Funds holding: 193 [Q4 2023] → 200 (+7) [Q1 2024]

2% less capital invested

Capital invested by funds: $6.55B [Q4 2023] → $6.44B (-$107M) [Q1 2024]

4% less call options, than puts

Call options by funds: $39M | Put options by funds: $40.6M

1.73% less ownership

Funds ownership: 85.66% [Q4 2023] → 83.93% (-1.73%) [Q1 2024]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q4 2023] → 9 (-1) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$45
8%
upside
Avg. target
$45
8%
upside
High target
$45
8%
upside

3 analyst ratings

positive
0%
neutral
100%
negative
0%
Mizuho
Graig Suvannavejh
8%upside
$45
Neutral
Maintained
16 Feb 2024
JP Morgan
Jessica Fye
8%upside
$45
Neutral
Maintained
28 Dec 2023
Jefferies
Michael Yee
8%upside
$45
Hold
Downgraded
22 Dec 2023

Financial journalist opinion

Based on 46 articles about CERE published over the past 30 days